|
May 5
|
Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts
|
|
Apr 15
|
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy
|
|
Apr 14
|
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
|
|
Apr 14
|
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
|
|
Apr 10
|
Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump’s Tariff Rollout
|
|
Mar 14
|
Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?
|
|
Mar 14
|
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
|
|
Mar 12
|
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
|
|
Feb 24
|
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
|
|
Feb 19
|
High Growth Tech Stocks To Watch In February 2025
|
|
Oct 9
|
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
|
|
Jul 17
|
China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
|
|
Jul 16
|
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
|
|
Jul 15
|
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
|
|
Jun 13
|
Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
|
|
Apr 11
|
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
|
|
Feb 29
|
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript
|
|
Feb 27
|
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results
|
|
Feb 27
|
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
|
|
Jan 10
|
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
|